Carisma Therapeutics Inc (NASDAQ: CARM) has experienced a rise in its stock price by 10.78 compared to its previous closing price of 0.40. However, the company has seen a fall of -3.20% in its stock price over the last five trading days. prnewswire.com reported 2024-12-09 that Resources realigned to focus primarily on in vivo macrophage engineering platform for fibrosis, oncology and autoimmune disease therapies Development of CT-0525 to be discontinued; workforce reduced by 34% PHILADELPHIA, Dec. 9, 2024 /PRNewswire/ — Carisma Therapeutics Inc. (Nasdaq: CARM ) (“Carisma” or the “Company”), a leader in macrophage-focused therapeutics, today announced a strategic reprioritization of its pipeline, cessation of development of CT-0525, and a reduction in the workforce by 34%. These measures will enable Carisma to focus its resources on advancing its in vivo macrophage engineering platform for the development of fibrosis, oncology and autoimmune disease therapies.
Is It Worth Investing in Carisma Therapeutics Inc (NASDAQ: CARM) Right Now?
CARM has 36-month beta value of 1.54. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 4 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CARM is 21.84M, and currently, short sellers hold a 2.60% ratio of that float. The average trading volume of CARM on December 27, 2024 was 218.77K shares.
CARM’s Market Performance
The stock of Carisma Therapeutics Inc (CARM) has seen a -3.20% decrease in the past week, with a -47.70% drop in the past month, and a -55.25% fall in the past quarter. The volatility ratio for the week is 11.11%, and the volatility levels for the past 30 days are at 11.19% for CARM. The simple moving average for the past 20 days is -27.23% for CARM’s stock, with a -63.70% simple moving average for the past 200 days.
Analysts’ Opinion of CARM
Many brokerage firms have already submitted their reports for CARM stocks, with Robert W. Baird repeating the rating for CARM by listing it as a “Neutral.” The predicted price for CARM in the upcoming period, according to Robert W. Baird is $1 based on the research report published on December 12, 2024 of the current year 2024.
BTIG Research gave a rating of “Buy” to CARM, setting the target price at $6 in the report published on April 11th of the current year.
CARM Trading at -46.22% from the 50-Day Moving Average
After a stumble in the market that brought CARM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.01% of loss for the given period.
Volatility was left at 11.19%, however, over the last 30 days, the volatility rate increased by 11.11%, as shares sank -48.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -53.46% lower at present.
During the last 5 trading sessions, CARM fell by -3.20%, which changed the moving average for the period of 200-days by -81.89% in comparison to the 20-day moving average, which settled at $0.6074. In addition, Carisma Therapeutics Inc saw -84.91% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CARM
Current profitability levels for the company are sitting at:
- -3.29 for the present operating margin
- 0.8 for the gross margin
The net margin for Carisma Therapeutics Inc stands at -3.15. The total capital return value is set at -2.12. Equity return is now at value -362.79, with -85.73 for asset returns.
Currently, EBITDA for the company is -85.89 million with net debt to EBITDA at 0.37. When we switch over and look at the enterprise to sales, we see a ratio of -0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.23.
Conclusion
To put it simply, Carisma Therapeutics Inc (CARM) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
